Tvardi Therapeutics, Inc.
Tvardi Therapeutics, Inc. (Nasdaq: TVRD) is a clinical-stage biopharmaceutical company developing oral small-molecule therapies that directly inhibit STAT3 for inflammatory and proliferative diseases. Its pipeline includes TTI-101, a direct STAT3 inhibitor in Phase 1b/2 development for hepatocellular carcinoma, and… From the company’s description.
In fiscal 2025, Tvardi Therapeutics, Inc. reported a net loss of $18.21M. Operations used $23.50M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Tvardi Therapeutics, Inc. does
In the company’s own words
Tvardi Therapeutics, Inc. (Nasdaq: TVRD) is a clinical-stage biopharmaceutical company developing oral small-molecule therapies that directly inhibit STAT3 for inflammatory and proliferative diseases. Its pipeline includes TTI-101, a direct STAT3 inhibitor in Phase 1b/2 development for hepatocellular carcinoma, and TTI-109, an oral phosphate prodrug designed to convert into TTI-101 and being evaluated in a Phase 1 trial in healthy volunteers. The company has also studied TTI-101 in idiopathic pulmonary fibrosis; its Phase 2 study did not meet its goals, and the company is evaluating the results. Tvardi has no reportable business segments described in the available text. In April 2025, Cara Therapeutics merged with Legacy Tvardi, changed its name to Tvardi Therapeutics, and continued Legacy Tvardi’s business. The company reports no revenue to date. Its website is https://www.tvarditherapeutics.com/.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- SUGAR LAND, TX
- Fiscal year end
- December
- CIK
- 1346830
- SIC
- 2834
Financial performance, year by year
Fiscal 2014–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Tvardi Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Tvardi Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Tvardi Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Tvardi Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Tvardi Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”